National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Hedgehog antagonist GDC-0449
An orally bioavailable small molecule with potential antineoplastic activity. Hedgehog antagonist GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. The Hedgehog signaling pathway plays an important role in tissue growth and repair; aberrant constitutive activation of Hedgehog pathway signaling and uncontrolled cellular proliferation may be associated with mutations in the Hedgehog-ligand cell surface receptors PTCH and SMO. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:GDC-0449



Previous:HDAC inhibitor PCI-24781, HDAC inhibitor SB939, HDAC/EGFR/Her2 inhibitor CUDC-101, HDM2 antagonist JNJ-26854165, Hectorol
Next:Hematide, hemiasterlin analog E7974, hepatitis A vaccine, hepatitis B vaccine, Hepsera

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov